Aulos Bioscience
United States
- Larkspur, California
- 01/08/2023
- Series A
- $20,000,000
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems towards killing tumor cells.
Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors.
The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- Industry Biotechnology Research
- Website https://aulosbio.com/
- LinkedIn https://www.linkedin.com/company/aulos-bioscience/
dazzle ai | $8,000,000 | (Jan 7, 2026)
Tesoro XP, Inc. | $5,400,000 | (Jan 7, 2026)
Lemon Slice | $10,500,000 | (Jan 7, 2026)
Array Labs | $20,000,000 | (Jan 7, 2026)
Lyte | $107,000,000 | (Jan 7, 2026)
Lucidean | $18,000,000 | (Jan 7, 2026)
CHAMP | $55,000,000 | (Jan 7, 2026)
Truemed | $34,000,000 | (Jan 7, 2026)
Coinbax | $4,200,000 | (Jan 7, 2026)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ciphero | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)